<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Poverty</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Poverty</journal-id><journal-title-group><journal-title>Infectious Diseases of Poverty</journal-title></journal-title-group><issn pub-type="epub">2049-9957</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5371198</article-id><article-id pub-id-type="pmid">28351414</article-id><article-id pub-id-type="publisher-id">286</article-id><article-id pub-id-type="doi">10.1186/s40249-017-0286-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scoping Review</subject></subj-group></article-categories><title-group><article-title>Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bergquist</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Utzinger</surname><given-names>J&#x000fc;rg</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Keiser</surname><given-names>Jennifer</given-names></name><address><email>jennifer.keiser@unibas.ch</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Ingerod, Brastad, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0587 0574</institution-id><institution-id institution-id-type="GRID">grid.416786.a</institution-id><institution/><institution>Swiss Tropical and Public Health Institute, </institution></institution-wrap>P.O. Box, CH-4002 Basel, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0642</institution-id><institution-id institution-id-type="GRID">grid.6612.3</institution-id><institution/><institution>University of Basel, </institution></institution-wrap>P.O. Box, CH-4003 Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>74</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel. There is a pressing need for new drugs against this disease whose control entirely depends on this single drug that has been widely used over the past 40&#x000a0;years. We argue that a broader anthelminthic approach supplementing praziquantel with new antischistosomals targeting different parasite development stages would not only increase efficacy but also reduce the risk for drug resistance. Repositioning drugs already approved for other diseases provides a shortcut to clinical trials, as it is expected that such drugs rapidly pass the regulatory authorities. The antischistosomal properties of antimalarial drugs (e.g., semisynthetic artemisinins, synthetic trioxolanes, trioxaquines and mefloquine) and of drugs being developed or registered for other purposes (e.g., moxidectin and miltefosin), administered alone or in combination with praziquantel, have been tested in the laboratory and clinical trials. Another avenue to follow is the continued search for new antischistosomal properties in plants. Here, we summarise recent progress made in schistosomiasis chemotherapy, placing particular emphasis on repositioning of existing drugs against schistosomiasis.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s40249-017-0286-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chemotherapy</kwd><kwd>Drug repositioning</kwd><kwd>Elimination</kwd><kwd>Morbidity control</kwd><kwd>Praziquantel</kwd><kwd>Schistosomiasis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>ERC-2013-CoG 614739-A_HERO</award-id><principal-award-recipient><name><surname>Keiser</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Multilingual abstracts</title><p>Please see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for translations of the five official working languages of the United Nations.</p></sec><sec id="Sec2"><title>Background</title><p>Schistosomiasis describes a complex of acute and mainly chronic helminth infection with considerable adverse influence on people&#x02019;s health and wellbeing [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The disease is one of today&#x02019;s foremost neglected tropical diseases (NTDs) and a disease of poverty [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The global burden of schistosomiasis is estimated at 2.6 million disability-adjusted life years (DALYs) [<xref ref-type="bibr" rid="CR5">5</xref>]. Although the number of healthy days lost annually is far below those calculated for HIV/AIDS, malaria and tuberculosis, the perceived importance of schistosomiasis is now more realistic than 10&#x02013;15 years ago. Indeed, due to the inclusion of also mild symptoms, such as anaemia, diarrhoea, dysuria and exercise intolerance [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], which were not previously counted by the Global Burden of Disease (GBD) study, schistosomiasis now comes second on the list of 18 (after the intestinal nematodes that are counted together) NTDs put forth by the World Health Organization (WHO) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Schistosomiasis is caused by one of six different species of the trematode worm <italic>Schistosoma</italic>, with the great majority of cases either infected with <italic>Schistosoma haematobium</italic>, <italic>S. japonicum</italic> or <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The African continent harbours both <italic>S. haematobium</italic> and <italic>S. mansoni</italic> with an estimated 90% of all cases in the world concentrated in sub-Saharan Africa [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. <italic>S. mansoni</italic> additionally occurs in Latin America, most importantly in Brazil [<xref ref-type="bibr" rid="CR11">11</xref>], while <italic>S. japonicum</italic> remains endemic in seven provinces of the People&#x02019;s Republic of China, The Philippines and three small Indonesian foci [<xref ref-type="bibr" rid="CR12">12</xref>]. <italic>S. guineensis</italic>, <italic>S. intercalatum</italic> and <italic>S. mekongi</italic> are not only in a clear minority, but also geographically limited; the former two along parts of the Congo River and in lower Guinea on the African continent [<xref ref-type="bibr" rid="CR13">13</xref>], while <italic>S. mekongi</italic> is restricted to small foci around the border between Cambodia and Lao People&#x02019;s Democratic Republic [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The pathology characterising schistosomiasis is primarily the result of immune responses against schistosome eggs trapped in the tissues, but blood loss caused by the adult worm is also an important symptom. Haematuria and dysuria are typical early signs of the urogenital form of the infection (caused by <italic>S. haematobium</italic>) with kidneys and bladder becoming seriously affected in chronic infections [<xref ref-type="bibr" rid="CR15">15</xref>]. The intestinal form (caused by any of the five other species) results in blood in the stool and diarrhoea with the liver and spleen affected in the longer term [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Morbidity has been strongly suppressed as a result of preventive chemotherapy that is the periodic large-scale administration of praziquantel to school-aged children and other high-risk groups without prior diagnosis [<xref ref-type="bibr" rid="CR16">16</xref>]. A systematic review and geostatistical analysis pertaining to schistosomiasis in sub-Saharan Africa suggests that the prevalence and distribution of the disease has declined in recent years, most likely as a result of preventive chemotherapy, coupled with social and economic development [<xref ref-type="bibr" rid="CR10">10</xref>]. Of note, in 2015, among the 218.7 million people requiring preventive chemotherapy against schistosomiasis, 65.2 million people were administered praziquantel, owing to a global coverage of 29.8% [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Praziquantel, a highly efficacious pyrazinoisoquinoline derivative with a good safety profile and a broad spectrum against helminth infections, remains the drug of choice for schistosomiasis chemotherapy since almost 40&#x000a0;years [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Thanks to the good therapeutic and safety index [<xref ref-type="bibr" rid="CR20">20</xref>], and a donation programme from Merck, praziquantel is the cornerstone in the WHO promoted global strategy against schistosomiasis. Despite reports of strains that have become tolerant or even resistant to praziquantel [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>], these findings are of little clinical relevance thus far. In the late 1970s/early 1980s, praziquantel replaced the first useful antischistosomal drugs oxamniquine, another quinoline derivative effective against <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], and metrifonate, an insecticide based on inhibition of acetyl-cholinesterase that is efficacious against <italic>S. haematobium</italic> [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Before that, in the early part of the 1900s (up to around 1975), a number of less efficacious compounds were used in spite of major adverse events, e.g., hycanthone, luchantone, amoscanate, niridazole and oltipraz. Antimony potassium tartrate, a potentially poisonous metalloid without distinctive effect, but known as an emetic and medicine against various ailments since ancient times marked the end of non-specific schistosomiasis chemotherapy [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p>Schistosomiasis control is at a pivotal point in major endemic areas. Elimination has been articulated as an aspiration, but it is clear that it cannot be based on praziquantel alone [<xref ref-type="bibr" rid="CR29">29</xref>]. The emphasis on preventive chemotherapy campaigns using praziquantel has led to the misconception that there is little need for alternative compounds. Drug discovery run by academic research groups rather than industry has resulted in a variety of new leads, which might serve as starting points for antischistosomal drug discovery. We review progress in research and development of antischistosomal drugs and update the intriguing field how new and old drugs can be utilized in concert against schistosomes in different developmental stages. Our focus is on repositioning of drugs used against diseases other than schistosomiasis, as this strategy might advance existing drugs more rapidly into clinical use for a typical disease of poverty with a deficient market.</p></sec><sec id="Sec3"><title>Research and development of antischistosomal drugs</title><sec id="Sec4"><title>Setting the scene</title><p>The WHO road map for the global control of the NTDs includes schistosomiasis [<xref ref-type="bibr" rid="CR30">30</xref>]. However, control &#x02013; let alone elimination &#x02013; of schistosomiasis has proven difficult because of rapid re-infection due to limited means of control for the intermediate host snail and absence of sanitary facilities in most endemic areas [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. A variety of approaches, including water, sanitation and hygiene (WASH), information, education and communication (IEC), behavioural change and snail control, have been employed, but preventive chemotherapy with praziquantel has been the fundamental approach since the early 1980s. If, for any reason, this line of attack would falter, there is currently no other remedy to put in its place and the next generation of anthelminthic drugs is yet to appear. Since the last surge of drug discovery for parasitic worm diseases in the 1970s, resulting in the marketing of praziquantel and ivermectin that, together, cure several of the major helminth infections [<xref ref-type="bibr" rid="CR33">33</xref>], no new drugs for helminthiases have been approved. It is even more worrisome that the drug discovery and development pipeline for NTDs has run dry over the past 40&#x000a0;years [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Pre-emptive action is urgently needed to assure that chemotherapy does not dwindle, particularly not in low- and middle-income countries where schistosomiasis inflicts a disproportionately high burden of disease. Judging from the veterinary field, development of drug resistance in helminthiasis can be swift [<xref ref-type="bibr" rid="CR35">35</xref>] and the situation with respect to malaria is a constant reminder of this risk [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec5"><title>Laboratory studies</title><p>The search for new drugs against schistosomiasis has taken various directions, including testing natural compounds, target-based drug discovery or compounds marketed for other indications. Phenotypic screens play an important role in antischistosomal drug discovery [<xref ref-type="bibr" rid="CR37">37</xref>] and many products of potential value have been found this way.</p><p>Natural plant products are an important source of antiparasitic drugs [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. This is not only potentially fruitful with respect to isolation of new active principles, but would also facilitate the elucidation of their mechanism of action. Herbal extracts have drawn attention due to their broad range of biological activity and the large variety of chemical structures presented. This untapped source of potential anthelminthic compounds remains a novelty and many papers on this topic exist. For example, a search on PubMed on January 23, 2017 using the search terms &#x02018;plant extract&#x02019; and &#x02018;schistosomiasis&#x02019; yielded 227 publications, while &#x02018;plant extract&#x02019; and &#x02018;<italic>Schistosoma</italic>&#x02019; yielded 194. It should, however, be noted that not only hits active against schistosomes but also against the snail intermediate host (plant molluscicides) and sometimes against other parasites were discovered [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>Another strategy is based on using available biologically active natural compounds and their directed chemical modification as recently demonstrated for new triphenylphosphonium derivatives of betulin and betulinic acid [<xref ref-type="bibr" rid="CR41">41</xref>]. However, rather than discussing the many different schistosomicidal agents discovered in plant extracts here, we refer to recent reviews of the field by de Moraes [<xref ref-type="bibr" rid="CR42">42</xref>] and Neves and colleagues [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>The recent sequencing of the genomes of the three key schistosome species has resulted in the discovery of many new possible vaccine and drug targets [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, it is conceivable that drug discovery programmes using molecular modelling strategies will increasingly contribute to antischistosomal drug discovery [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p>Work on the antischistosomal properties of various antimalarial drugs, notably semi-synthetic artemisinins, synthetic trioxolanes and mefloquine [<xref ref-type="bibr" rid="CR49">49</xref>], as well as a few more discussed below, have shown that repurposing of drugs may be the more rapid approach as it provides a shortcut to clinical trials and rapid passage through regulatory authorities. Indeed, the idea of repositioning drugs is an inexpensive, yet effective source of new lead compounds for use against schistosomiasis, which has already resulted in several promising leads [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p>While the antimalarials are the most well-known group of drugs shown to have a strong action against schistosomes in addition to what they are intended for [<xref ref-type="bibr" rid="CR49">49</xref>] several other pharmaceutical groups also contain compounds with such effect, notably drugs used for cancer therapy [<xref ref-type="bibr" rid="CR51">51</xref>]. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> contains a list of candidate drugs described in some detail with regard to use against schistosomiasis summarising their effect on adult and juvenile schistosomes, including dosage.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Activity observed with drug discovery candidates in the <italic>S. mansoni-</italic>mouse model</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chemical compound/drug</th><th>Dose</th><th>Worm burden reduction (adult)</th><th>Worm burden reduction (juvenile)</th><th>Reference</th></tr></thead><tbody><tr><td>Artemether</td><td>300&#x000a0;mg/kg/day for 2&#x000a0;days</td><td>85.4&#x02013;98.3%</td><td>70%</td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td>Artesunate</td><td>150 or 300&#x000a0;mg/kg/day for 7&#x000a0;days</td><td>34&#x02013;49%</td><td>67&#x02013;77%</td><td>[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td>Bisquinoline cyclen derivative</td><td>400&#x000a0;mg/kg single dose</td><td>12.3%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td>Bisquinoline cyclen derivative (Fe<sup>++</sup> complex)</td><td>400&#x000a0;mg/kg single dose</td><td>88.4%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td>Bisquinoline cyclen derivative (Mn<sup>++</sup> complex)</td><td>400&#x000a0;mg/kg single dose</td><td>74.5%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td>Chlorambucil</td><td>2.5&#x000a0;mg/kg/day for 5&#x000a0;days</td><td>22.7%</td><td>75.8%</td><td>[<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td>Clofazimine</td><td>400&#x000a0;mg/kg single dose</td><td>82.7%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td>2,3-dianilinoquinoxaline MMV007224</td><td>400&#x000a0;mg/kg single dose</td><td>40.8%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td>N,N&#x02019;-Diarylurea MMV665852</td><td>400&#x000a0;mg/kg single dose</td><td>52.5%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td>N,N&#x02019;-Diarylurea MMV665852 analogs</td><td>400&#x000a0;mg/kg single dose</td><td>9.3&#x02013;36%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td>Doramectin</td><td>10&#x000a0;mg/kg single dose</td><td>60.1%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td>Mefloquine</td><td>400&#x000a0;mg/kg single dose (adult), 100&#x000a0;mg/kg (juvenile)</td><td>77.3%</td><td>94.2%</td><td>[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td>Mefloquine derivatives</td><td>100 mg/kg single dose</td><td>0-87%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td>Miltefosin</td><td>20&#x000a0;mg/kg daily for 5&#x000a0;days</td><td>95.4%</td><td>75.5%</td><td>[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td>OZ78</td><td>200&#x000a0;mg/kg single dose (juvenile), 400&#x000a0;mg/kg single dose (adult)</td><td>0%</td><td>82%</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td>OZ209</td><td>200&#x000a0;mg/kg single dose (juvenile), 400&#x000a0;mg/kg single dose (adult)</td><td>16%</td><td>85%</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td>OZ288</td><td>200&#x000a0;mg/kg single dose (juvenile), 400&#x000a0;mg/kg single dose (adult)</td><td>52.2%</td><td>95.4%</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td>OZ418</td><td>200&#x000a0;mg/kg single dose (juvenile), 400&#x000a0;mg/kg single dose (adult)</td><td>80%</td><td>100%</td><td>[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td>Perhexiline maleate</td><td>23, 70 and 400&#x000a0;mg/kg single dose</td><td>Not given</td><td>Not given</td><td>[<xref ref-type="bibr" rid="CR83">83</xref>]</td></tr><tr><td>Piperaquine/OZ277 (Synriam)</td><td>40&#x000a0;mg/kg arterolane (OZ277) and 200&#x000a0;mg/kg piperaquine</td><td>88.7%</td><td>85.4%</td><td>[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td>Ferroquine</td><td>200&#x000a0;mg/kg and 800&#x000a0;mg/kg single dose</td><td>19.4% and 35.6%</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr></tbody></table></table-wrap>
</p><sec id="Sec6"><title>Antimalarials</title><p>Natural products have played a major role in drug discovery, in particular for malaria treatment and prophylaxis. While quinine and artemisinin come straight from natural plants, several semi-synthetic agents (e.g., artemether and artesunate) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] and synthetic derivatives have been at the centre of attention for more than 15&#x000a0;years. Hybrid molecules comprising of a 1,2,4-trioxane domain (as in the artemisinins) linked to amino quinoline (as in chloroquine) were developed in the late 1990s; these trioxaquines thus have a dual mechanism of action, which improves the antimalarial activity over each single compound [<xref ref-type="bibr" rid="CR54">54</xref>]. Meanwhile, some trioxaquines have also been analysed for their antischistosomal properties with promising results [<xref ref-type="bibr" rid="CR55">55</xref>], suggesting that the heme molecule is an important target for these compounds [<xref ref-type="bibr" rid="CR56">56</xref>]. The mechanisms of action of the 1,2,4-trioxolanes remains unknown but is clearly connected with the peroxide bond, which they share with the artemisinins. The compounds OZ78, OZ209 and OZ288 were first studied in <italic>S. mansoni</italic>- and <italic>S. japonicum</italic>-rodent models [<xref ref-type="bibr" rid="CR57">57</xref>] and several representative compounds with high antischistosomal activity were identified, some of which &#x02013; such as OZ418 &#x02013; have improved pharmacokinetic properties [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. The highest activity (worm burden reduction of 72%) was seen after treating hamsters infected with adult <italic>S. mansoni</italic> with OZ288 [<xref ref-type="bibr" rid="CR57">57</xref>] and mice with OZ418 (worm burden reduction of 86%) [<xref ref-type="bibr" rid="CR59">59</xref>]. Recently, using rodents infected with <italic>S. mansoni</italic>, Mossallam and colleagues showed high activity of OZ277 combined with piperaquine phosphate, a bisquinoline first synthesised in the 1960s and used extensively in the People&#x02019;s Republic of China until resistant strains of <italic>Plasmodium falciparum</italic> arose [<xref ref-type="bibr" rid="CR61">61</xref>]. Bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, bridged 1,2,4-trioxolanes, silyl peroxides and hydroxylamines were also studied with the highest antischistosomal activity (in particular in vitro) observed for trioxolanes and tricyclic monoperoxides [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p>Van Nassauw et al. [<xref ref-type="bibr" rid="CR63">63</xref>] were the first to report an antischistosomal effect by mefloquine, an effective antimalarial agent that was introduced as a successor to chloroquine [<xref ref-type="bibr" rid="CR64">64</xref>]. They noted that mefloquine significantly reduces egg production in <italic>S. mansoni</italic>-infected mice but they saw no effect on worm burden. Later papers also reported impact on egg maturation but in contrast to this first paper, researchers all noted strong effect with respect to worm burden [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>]. When different amino ethanols, such as halofantrine, lumefantrin, quinine and mefloquine, were tested in <italic>S. mansoni</italic>-infected mice, mefloquine showed the highest activity [<xref ref-type="bibr" rid="CR65">65</xref>]. A further important finding is that, in contrast to the effect by artemisinins and praziquantel that target juvenile and adult schistosomes, respectively, all parasite stages are equally affected by mefloquine [<xref ref-type="bibr" rid="CR65">65</xref>]. Only moderate stereoselectivity was observed testing the activities of the erythro and threo isomers and racemates of mefloquine [66]. In addition, mefloquine had a strong effect on tissue egg load and number of liver granulomas [67]. Additionally, activity has been shown against <italic>S. japonicum</italic> [<xref ref-type="bibr" rid="CR68">68</xref>] and <italic>S. haematobium</italic> [<xref ref-type="bibr" rid="CR69">69</xref>]. Moreover, synergistic effects were observed when mefloquine and praziquantel were combined in the animal model [<xref ref-type="bibr" rid="CR70">70</xref>]. Finally, when evaluating the antischistosomal activities of nine mefloquine-related compounds belonging to the 4-pyridinemethanols, 9-phenanthrenmethanols, and 4-quinolinemethanols, high activity was observed for WR7930 and enpiroline, an antimalarial drug, which had already undergone clinical testing [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p>Another approach is represented by the screening of a library for antischistosomal properties in 200 diverse drug-like and 200 probe-like compounds with confirmed in vitro activity against <italic>P. falciparum</italic> obtained from the Medicines for Malaria Venture (MMV). Thirty-four compounds were found active in in vitro screens, two of which (N,N&#x02019;-diarylurea and 2,3-dianilinoquinoxaline) identified as early leads after extensive in vitro and in vivo testing; they also had good pharmacokinetic profiles and low cytotoxic potential. In more detail, in vivo experimental work with <italic>S. mansoni</italic> revealed worm burdens reductions of 53% and 41%, respectively, compared to controls [<xref ref-type="bibr" rid="CR71">71</xref>]. Follow-up studies evaluated the structure-activity relationships of 46 commercially available analogues of MMV665852 larval and adult <italic>S. mansoni</italic> worms in vitro with subsequent in vivo studies. Despite satisfactory in vitro results and <italic>in silico</italic> predictions, only one compound resulted in a statistically significant worm burden reduction (66%) in <italic>S. mansoni</italic>-infected mice. The authors concluded that there is a need to synthesise compounds with improved solubility and pharmacokinetic properties [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p>The ferrocenyl analogue of chloroquine, ferroquine, is an antimalarial in late-stage drug development. However, the drug revealed only moderate in vitro activity against both larval and adult stages of <italic>S. mansoni</italic> and low in vivo activity [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p>Further, a series of synthetic tetra-azamacrocyclic derivatives and their metal complexes, which are effective antimalarial agents were synthesised, characterised and screened in vitro against different schistosomal stages (schistosomula and adult worms). Three compounds (the bisquinoline derivative of cyclen and its Fe<sup>2+</sup> and Mn<sup>2+</sup> complexes), highly active in vitro, were selected for in vivo experiments using the <italic>S. mansoni</italic>-mouse model. The worm burden reductions were 12%, 88% and 75%, respectively. The additional fact that the Fe<sup>2+</sup>complex exhibited an activity comparable to that of praziquantel must be deemed a strong indication of a novel drug lead for schistosomiasis [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec7"><title>Anticancer drugs</title><p>It has further been demonstrated that miltefosine, an anticancer alkylphosphocholine, possesses significant activity against different developmental stages of <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR75">75</xref>]. This lead has been further developed using a nanotechnological adjuvant approach based on lipid nanocapsules [<xref ref-type="bibr" rid="CR76">76</xref>]. The results of this study indicated a strong schistosomicidal effects against both the invasive and the immature stage, further indicated by a significant reduction in worm burdens [<xref ref-type="bibr" rid="CR76">76</xref>].</p><p>Chlorambucil, a nitrogen mustard alkylating agent that has so far mainly been used in the treatment of chronic lymphocytic leukemia, low-grade non-Hodgkin&#x02019;s lymphoma and Hodgkin&#x02019;s disease, and is on the WHO list of essential medicines, recently demonstrated an antischistosomal in vitro effect in the form of progressive reductions of worm viability in a dose-dependent manner [<xref ref-type="bibr" rid="CR77">77</xref>]. In vivo, chlorambucil induced a significant reduction in the total worm (<italic>S. mansoni</italic>) burden, including 89% and 87% intestinal and hepatic egg count reduction, respectively, with the highest in vivo efficacy against the juvenile stage of <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p>Cowan et al. studied the approved oncology drug set of the National Cancer Institute&#x02019;s Developmental Therapeutic Program against <italic>S. mansoni</italic> in vitro and in vivo. Of six compounds studied in vivo, the highest activity was observed with two kinase inhibitors &#x02013; trametinib and vandetanib with respective worm burden reductions of 63.6% and 48.1% &#x02013; after a single oral dose of 400&#x000a0;mg/kg [<xref ref-type="bibr" rid="CR78">78</xref>]. In schistosomes, conserved protein kinases possess pivotal roles contributing not only to reproduction processes, but also to the pathology of schistosomiasis [<xref ref-type="bibr" rid="CR79">79</xref>]. Kinases represent therefore attractive targets for new-generation antischistosomal drugs.</p></sec><sec id="Sec8"><title>Miscellaneous products</title><p>The aryl hydantoin Ro 13&#x02013;3978 is a compound discovered by Hoffmann-La Roche more than two decades ago with good in vivo antischistosomal activity [<xref ref-type="bibr" rid="CR80">80</xref>]. Ro 13&#x02013;3978 is structurally similar to the antiandrogenic drug nilutamide, which has moderate antischistosomal properties [<xref ref-type="bibr" rid="CR81">81</xref>]. To reduce the antiandrogenic effect, Wang and colleagues designed a number of analogs incorporating substructures and functional groups and identified several compounds with high antischistosomal efficacy that were less antiandrogenic [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p>Other unrelated drugs have also received interest. For example, a recent report has shown that perhexiline maleate, a drug used for heartburn (angina) by improving myocardial oxygen utilization, surprisingly reacted when a library with an ATP-based luminescent assay based on <italic>S. mansoni</italic> schistosomula was screened [<xref ref-type="bibr" rid="CR83">83</xref>]. This drug was found to exhibit a marked lethal effect on all <italic>S. mansoni</italic> parasite life stages in vivo resulting in tegumental damage in the adult male worm and impaired egg production in the female worm [<xref ref-type="bibr" rid="CR83">83</xref>]. Although the preliminary in vivo experiments only resulted in moderate egg reductions, this drug warrants deeper investigation and if found as useful clinically as the in vivo experiments indicate (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), the road to registration should be short.</p><p>In another scheme, researchers found 121 compounds active against <italic>S. mansoni</italic> schistosomula out of 1 600 compounds approved by United States&#x02019; Food and Drug Administration (FDA). When advancing to an adult worm screen, the list shrank by more than 70% and when available pharmacokinetic and toxicity data for these compounds were considered, only 11 remained, two of which (i.e., doramectin and clofazimine) resulted in worm burden reductions of 60% and 83%, respectively, when tested in vivo against <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR84">84</xref>]. These two active drugs are widely available and constitute excellent starting points for developing novel drug classes against schistosomiasis.</p><p>Similarly, Abdulla et al. [<xref ref-type="bibr" rid="CR85">85</xref>] tested a large number of natural and synthetic compounds against <italic>S. mansoni</italic> schistosomula, many of which were approved drugs to find starting points for developing new leads. The various compounds identified have been posted online as a community resource.</p></sec></sec><sec id="Sec9"><title>Clinical studies</title><p>Drug discovery and follow-up development is an expensive endeavour. Repositioning of drugs already approved for human use offers a way out of this impasse, at least from the part of the studies concerned with safety. Phase II/IV clinical trials are still needed to make sure that the drugs work as planned with respect to the pathogens they are supposed to protect against. In an endeavour to find drugs against schistosomiasis, antimalarials were the most widely studied drugs, as summarised in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of four recent clinical trials with drugs repositioned for use against chronic infections with <italic>S. mansoni</italic> and <italic>S. haematobium</italic>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Compound</th><th colspan="2">
<italic>S. mansoni</italic>
</th><th colspan="2">
<italic>S. haematobium</italic>
</th><th rowspan="2">Reference</th></tr><tr><th>Cure rate<break/>(%)</th><th>Egg reduction rate<break/>(%)</th><th>Cure rate<break/>(%)</th><th>Egg reduction rate<break/>(%)</th></tr></thead><tbody><tr><td>Artesunate</td><td>Not done</td><td>Not done</td><td>25</td><td>85</td><td>[<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td>Mefloquine</td><td>Not done</td><td>Not done</td><td>21</td><td>74</td><td>[<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td>Mefloquine-artesunate</td><td>Not done</td><td>Not done</td><td>61</td><td>96</td><td>[<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td>Mefloquine-artesunate-praziquantel</td><td>Not done</td><td>Not done</td><td>29</td><td>96</td><td>[<xref ref-type="bibr" rid="CR105">105</xref>]</td></tr><tr><td>Moxidectin</td><td>13</td><td>71</td><td>15</td><td>9</td><td>[<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td>Synriam</td><td>7</td><td>65</td><td>11</td><td>0</td><td>[<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td>Praziquantel-Synriam</td><td>27</td><td>78</td><td>60</td><td>96</td><td>[<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td>ARA Arachidonic acid</td><td>13&#x02013;50</td><td>0&#x02013;64</td><td>Not done</td><td>Not done</td><td>[<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr></tbody></table></table-wrap>
</p><p>The artemisinins have been discussed extensively in previous reviews [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR86">86</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>]. Briefly, leaf extracts from the plant <italic>Artemisia annua</italic> recommended in Chinese traditional medicine against malaria (and other ailments), constituted the starting point for the development of the artemisinin-based combination therapy (ACT) currently in use against this infection [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. The expansion of the therapeutic effect of the artemisinins from <italic>Artemisia</italic> leaves to include <italic>S. japonicum</italic> schistosomes discovered in the early 1980s was completely unexpected [<xref ref-type="bibr" rid="CR94">94</xref>]. This effect by the semi-synthetic artemisinin derivative artemether was later also confirmed for <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR52">52</xref>] and <italic>S. haematobium</italic> [<xref ref-type="bibr" rid="CR95">95</xref>] in experimental animals. Subsequent clinical trials confirmed the protective efficacy for artemether [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>] and artesunate [<xref ref-type="bibr" rid="CR98">98</xref>] and encouraged many articles discussing the advantage (and potential disadvantages) of including the artemisinins along with praziquantel in areas endemic for schistosomiasis and co-endemic for malaria [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR90">90</xref>].</p><p>In more detail, the antischistosomal effect of the artemisinins is primarily directed against juvenile schistosomes, while that of praziquantel works on the very day of infection, after which the parasite does not become susceptible against this drug again until it reaches adulthood 4&#x02013;5 weeks later [<xref ref-type="bibr" rid="CR87">87</xref>]. Although the periods of susceptibility vary slightly between the different schistosome species infective to man, the principle of age-correlated impact remains the same. Surprisingly, but advantageously, the drugs thus complement each other [<xref ref-type="bibr" rid="CR87">87</xref>]. Currently, preventive chemotherapy is based on the administration of praziquantel only, which means that only adult worms are killed and that the person treated will be fully repopulated from surviving schistosomula about a month later. Combination therapy would improve the situation but it must also be iterated for as long as the patient lives in an endemic area if precautions against reinfection are not taken (which is difficult and costly in practice). The risk for drug resistance due to widespread use of monotherapy with artemether or artesunate, however, must be taken seriously as the emergence of malaria parasites resistant to the artemisinins have shown [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. However, used in non-malarious areas, this risk should be limited.</p><p>There is no single prophylactic drug that can reliably protect against schistosome infection, but the combination of praziquantel and artemether comes close [<xref ref-type="bibr" rid="CR101">101</xref>]. On the other hand, the use of this kind of prophylaxis can only be recommended in very special cases; for example during flood relief work in the People&#x02019;s Republic of China and perhaps when the final steps of elimination of the infection are taken.</p><p>Arterolane maleate (OZ277) is one of the first fully synthetic non-artemisinin antimalarial compounds marketed, hence offering a treatment alternative to the artemisinins (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The arterolane maleate/piperaquine combination, licensed in 2011 as an antimalarial drug under the name of Synriam&#x000ae; [<xref ref-type="bibr" rid="CR102">102</xref>], has been investigated for activity against chronic schistosome infections in humans. Two single-blind, randomised exploratory Phase II trials have been carried out in adolescents infected with <italic>S. mansoni</italic> and <italic>S. haematobium</italic> in C&#x000f4;te d&#x02019;Ivoire with cure rate (CR) and egg reduction rate (ERR) based on geometric mean and safety as endpoints. Synriam&#x000ae; showed low efficacy against <italic>S. haematobium</italic> with CR and ERR of 11% and 0%, respectively. Against <italic>S. mansoni</italic> a CR of 7% and an ERR of 64.9% was observed [<xref ref-type="bibr" rid="CR103">103</xref>]. Despite the low efficacies observed it might be worthwhile to assess the efficacy of Synriam against juvenile schistosome infections.</p><p>A few years ago the efficacy and safety of mefloquine (25&#x000a0;mg/kg) was studied in a randomised, exploratory open-label trial against <italic>S. haematobium</italic>. The other treatment arms consisted of artesunate (3 doses of 4&#x000a0;mg/kg), mefloquine-artesunate (3 doses of 100&#x000a0;mg artesunate plus 250&#x000a0;mg mefloquine) and praziquantel (40&#x000a0;mg/kg) alone. CRs of mefloquine, artesunate, mefloquine-artesunate and praziquantel alone against <italic>S. haematobium</italic> at day 26 after treatment were 21%, 25%, 61% and 88%, respectively. Both mefloquine-artesunate and praziquantel alone revealed ERRs in excess of 95% [<xref ref-type="bibr" rid="CR104">104</xref>]. Based on the aforementioned report documenting synergistic effects when mefloquine and praziquantel were combined [<xref ref-type="bibr" rid="CR70">70</xref>], a thorough study investigating combination therapy for <italic>S. haematobium</italic> infection in human subjects was initiated. When praziquantel-mefloquine and praziquantel-mefloquine-artesunate combinations were used, the investigators could not find any increased efficacy compared to praziquantel alone (CRs from 26% to 33%), but they observed a higher level of side effects with the mefloquine combinations [<xref ref-type="bibr" rid="CR105">105</xref>].</p><p>Moxidectin, a semisynthetic derivative of nemadectin produced by fermentation by <italic>Streptomyces cyanogriseus</italic> originally developed for the prevention and control of <italic>Dirofilaria</italic> immitis (heartworm) and intestinal worms in dogs [<xref ref-type="bibr" rid="CR106">106</xref>], is being assessed as an alternative to ivermectin in the treatment of onchocerciasis in humans. In the frame of this programme its effect on concomitant helminths revealed CR and ERR of 64% and 66%, respectively in <italic>S. mansoni</italic>-infected patients [<xref ref-type="bibr" rid="CR107">107</xref>]. The aforementioned study by Barda and colleagues recently demonstrated low efficacy of moxidectin against <italic>S. haematobium</italic> and low CR and moderate ERR against <italic>S. mansoni</italic> [<xref ref-type="bibr" rid="CR103">103</xref>].</p><p>Arachidonic acid (ARA), which is a normal constituent of cell plasma membranes was studied in schoolchildren with light, moderate or heavy <italic>S. mansoni</italic> infection given a good performance in a proof-of-concept study in children with light infections [<xref ref-type="bibr" rid="CR108">108</xref>]. ARA (10&#x000a0;mg/kg per day for 15&#x000a0;days) revealed moderate CRs (50% and 60%, respectively) against light infection and low CRs (21% and 20%, respectively) against heavy infection. Praziquantel and ARA combined elicited 83% and 78% CRs in children with light and heavy infection, respectively [<xref ref-type="bibr" rid="CR109">109</xref>].</p></sec></sec><sec id="Sec10"><title>Discussion</title><p>Praziquantel is currently the only fully effective antischistosomal drug in use [<xref ref-type="bibr" rid="CR25">25</xref>]. It has been used in preventive chemotherapy programmes in many endemic countries, in some continuously since more than 15&#x000a0;years [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. However, it is not until recently that preschool-aged children and pregnant women were included into the recommended target population for preventive chemotherapy [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Both these groups are now recommended to be treated with praziquantel when needed; still there are existing gaps due to drug shortage and lack of a pediatric praziquantel formulation [<xref ref-type="bibr" rid="CR112">112</xref>]. This expanded access to praziquantel, including biannual treatment schedules [<xref ref-type="bibr" rid="CR114">114</xref>] and use of the drug for the treatment of domestic animals in the context of zoonotic schistosomiasis [<xref ref-type="bibr" rid="CR115">115</xref>], increases the risk for development of resistance and demands augmented monitoring of drug failure and resistance.</p><p>Drug discovery is indeed essential, since the loss of praziquantel due to resistance would not only jeopardize the success achieved, but also close the window of opportunity for assembling an integrated approach, e.g., combining effective chemotherapy with a different approach with a longer reach, e.g., a vaccine [<xref ref-type="bibr" rid="CR116">116</xref>]. This aspiration rests, however, on fragile grounds as inadequate funding has held back vaccine development and even if some good advances have been made [<xref ref-type="bibr" rid="CR117">117</xref>], we are still years from potential field application of a schistosomiasis vaccine. In addition, new drugs are an unconditional necessity not only to safeguard the efficacy of chemotherapy, but also because an effect against both juvenile and adult schistosomes, would also affect transmission allowing longer intervals between preventive chemotherapy rounds.</p><p>Identification of the antischistosomal activity of the artemisinins constituted the impetus for investigating the properties of natural products with the aim of developing new treatments for various parasitic diseases. Although this progress represents a landmark in the advance towards completely new drugs against schistosomiasis (and also malaria), ongoing research on repositioning existing drugs has already resulted in a wide range of promising, antischistosomal drug candidates. Although no drug candidate with as good efficacy as that of praziquantel has appeared, many drugs show profiles and efficacies offering the prospect of together covering the whole spectrum from 1-day-old schistosomula up to adult worms such as the praziquantel-artemisinin combinations. Even drugs that have the same effect on schistosome worms can complement each other as long as their mechanisms of action differ.</p><p>Apart from the advances made with repositioning drugs, further development of trioxolanes and trioxaquines, as well investigation of plant extracts and screening of libraries, deserve further scientific inquiry. Continuing in these footsteps, we recommend establishing an international research programme for prospecting synthetic, semi-synthetic and bioactive compounds from natural products, including plant molluscicides. In vitro and in vivo evaluation of chemical constituents belonging to different classes of chemical compounds should obviously be part of this effort, as should structural determination using genomic and proteomic approaches.</p></sec><sec id="Sec11"><title>Conclusions</title><p>Summarising the progress in the field of antischistosomal drug discovery, the sad reality is that in 15&#x000a0;years&#x02019; time we will likely have no alternatives to praziquantel available. There is a pressing need to strengthen antischistosomal drug discovery, which includes improving the translational science in academia, intensify collaborative approaches, including engagement with the pharmaceutical industry and persuade donors and policy makers that alternatives to praziquantel are necessary for sustaining the control of schistosomiasis and approaching the goal of eliminating this scourge from mankind.</p><p>Research into how drugs act at the fundamental level is an important research area as this has a high probability of discovering superior formulations and combinations. Pursuing this approach, the following axes of research should be particularly rewarding:<list list-type="order"><list-item><p>profiling existing drugs and drug candidates with the aim of finding leads to superior derivatives;</p></list-item><list-item><p>investigation of different and more efficient combinations of existing drugs;</p></list-item><list-item><p>exploration of disparity between host and parasite metabolic pathways;</p></list-item><list-item><p>analysis of genomes and transcriptomes with the aim of identifying new drug targets; and</p></list-item><list-item><p>monitoring antischistosomal effects in areas where ACTs are used as first-line drugs against malaria.</p></list-item></list>
</p></sec></body><back><app-group><app id="App1"><sec id="Sec12"><title>Additional file</title><p>
<media position="anchor" xlink:href="40249_2017_286_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p>Multilingual abstracts in the five official working languages of the United Nations. (PDF 466&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><ack><title>Acknowledgements</title><p>We thank the Global Schistosomiasis Alliance for inviting us to prepare this article for a thematic issue of Infectious Diseases of Poverty.</p><sec id="FPar1"><title>Funding</title><p>Jennifer Keiser is grateful to the European Research Council (ERC-2013-CoG 614739-A_HERO) for financial support.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Does not apply.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>All authors contributed equally to the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>All authors have approved the manuscript for submission.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryseels</surname><given-names>B</given-names></name></person-group><article-title>Schistosomiasis</article-title><source>Infect Dis Clin North Am</source><year>2012</year><volume>26</volume><issue>2</issue><fpage>383</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2012.03.004</pub-id><?supplied-pmid 22632645?><pub-id pub-id-type="pmid">22632645</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colley</surname><given-names>DG</given-names></name><name><surname>Bustinduy</surname><given-names>AL</given-names></name><name><surname>Secor</surname><given-names>WE</given-names></name><name><surname>King</surname><given-names>CH</given-names></name></person-group><article-title>Human schistosomiasis</article-title><source>Lancet</source><year>2014</year><volume>383</volume><issue>9936</issue><fpage>2253</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61949-2</pub-id><?supplied-pmid 24698483?><pub-id pub-id-type="pmid">24698483</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molyneux</surname><given-names>DH</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Fenwick</surname><given-names>A</given-names></name></person-group><article-title>&#x0201c;Rapid-impact interventions&#x0201d;: how a policy of integrated control for Africa&#x02019;s neglected tropical diseases could benefit the poor</article-title><source>PLoS Med</source><year>2005</year><volume>2</volume><issue>11</issue><fpage>e336</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0020336</pub-id><?supplied-pmid 16212468?><pub-id pub-id-type="pmid">16212468</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>SL</given-names></name><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Blum</surname><given-names>J</given-names></name><name><surname>Neumayr</surname><given-names>AL</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Hatz</surname><given-names>CF</given-names></name></person-group><article-title>Neglected tropical diseases: diagnosis, clinical management, treatment and control</article-title><source>Swiss Med Wkly</source><year>2012</year><volume>142</volume><fpage>w13727</fpage><?supplied-pmid 23180107?><pub-id pub-id-type="pmid">23180107</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990&#x02013;2015: a systematic analysis for the Global Burden of Disease study 2015. Lancet 2016;388(10053):1603&#x02013;58.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>CH</given-names></name><name><surname>Dickman</surname><given-names>K</given-names></name><name><surname>Tisch</surname><given-names>DJ</given-names></name></person-group><article-title>Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis</article-title><source>Lancet</source><year>2005</year><volume>365</volume><issue>9470</issue><fpage>1561</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66457-4</pub-id><?supplied-pmid 15866310?><pub-id pub-id-type="pmid">15866310</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>CH</given-names></name><name><surname>Dangerfield-Cha</surname><given-names>M</given-names></name></person-group><article-title>The unacknowledged impact of chronic schistosomiasis</article-title><source>Chronic Illn</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1177/1742395307084407</pub-id><?supplied-pmid 18322031?><pub-id pub-id-type="pmid">18322031</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Alvarado</surname><given-names>M</given-names></name><name><surname>Bas&#x000e1;&#x000f1;ez</surname><given-names>MG</given-names></name><name><surname>Bolliger</surname><given-names>I</given-names></name><name><surname>Bourne</surname><given-names>R</given-names></name><name><surname>Boussinesq</surname><given-names>M</given-names></name><name><surname>Brooker</surname><given-names>SJ</given-names></name><name><surname>Brown</surname><given-names>AS</given-names></name><name><surname>Buckle</surname><given-names>G</given-names></name><name><surname>Budke</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The Global Burden of Disease study 2010: interpretation and implications for the neglected tropical diseases</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0002865</pub-id><?supplied-pmid 25058013?><pub-id pub-id-type="pmid">25058013</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Caffrey</surname><given-names>CR</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis</article-title><source>Acta Trop</source><year>2011</year><volume>120</volume><issue>Suppl 1</issue><fpage>S121</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2010.08.020</pub-id><?supplied-pmid 20831855?><pub-id pub-id-type="pmid">20831855</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>YS</given-names></name><name><surname>Biedermann</surname><given-names>P</given-names></name><name><surname>Ekpo</surname><given-names>UF</given-names></name><name><surname>Garba</surname><given-names>A</given-names></name><name><surname>Mathieu</surname><given-names>E</given-names></name><name><surname>Midzi</surname><given-names>N</given-names></name><name><surname>Mwinzi</surname><given-names>P</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Raso</surname><given-names>G</given-names></name><name><surname>Assar&#x000e9;</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><issue>8</issue><fpage>927</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00066-3</pub-id><?supplied-pmid 26004859?><pub-id pub-id-type="pmid">26004859</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholte</surname><given-names>RGC</given-names></name><name><surname>Gosoniu</surname><given-names>L</given-names></name><name><surname>Malone</surname><given-names>JB</given-names></name><name><surname>Chammartin</surname><given-names>F</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Vounatsou</surname><given-names>P</given-names></name></person-group><article-title>Predictive risk mapping of schistosomiasis in Brazil using Bayesian geostatistical models</article-title><source>Acta Trop</source><year>2014</year><volume>132</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2013.12.007</pub-id><?supplied-pmid 24361640?><pub-id pub-id-type="pmid">24361640</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Bergquist</surname><given-names>R</given-names></name><name><surname>Olveda</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name></person-group><article-title>Important helminth infections in Southeast Asia: diversity, potential for control and prospects for elimination</article-title><source>Adv Parasitol</source><year>2010</year><volume>72</volume><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(10)72001-7</pub-id><?supplied-pmid 20624526?><pub-id pub-id-type="pmid">20624526</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchuem Tchuent&#x000e9;</surname><given-names>LA</given-names></name><name><surname>Southgate</surname><given-names>VR</given-names></name><name><surname>Jourdane</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>BL</given-names></name><name><surname>Vercruysse</surname><given-names>J</given-names></name></person-group><article-title><italic>Schistosoma intercalatum</italic>: an endangered species in Cameroon?</article-title><source>Trends Parasitol</source><year>2003</year><volume>19</volume><issue>9</issue><fpage>389</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S1471-4922(03)00193-4</pub-id><?supplied-pmid 12957514?><pub-id pub-id-type="pmid">12957514</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muth</surname><given-names>S</given-names></name><name><surname>Sayasone</surname><given-names>S</given-names></name><name><surname>Odermatt-Biays</surname><given-names>S</given-names></name><name><surname>Phompida</surname><given-names>S</given-names></name><name><surname>Duong</surname><given-names>S</given-names></name><name><surname>Odermatt</surname><given-names>P</given-names></name></person-group><article-title><italic>Schistosoma mekongi</italic> in Cambodia and Lao People&#x02019;s Democratic Republic</article-title><source>Adv Parasitol</source><year>2010</year><volume>72</volume><fpage>179</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(10)72007-8</pub-id><?supplied-pmid 20624532?><pub-id pub-id-type="pmid">20624532</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Werf</surname><given-names>MJ</given-names></name><name><surname>de Vlas</surname><given-names>SJ</given-names></name><name><surname>Brooker</surname><given-names>S</given-names></name><name><surname>Looman</surname><given-names>CWN</given-names></name><name><surname>Nagelkerke</surname><given-names>NJD</given-names></name><name><surname>Habbema</surname><given-names>JDF</given-names></name><name><surname>Engels</surname><given-names>D</given-names></name></person-group><article-title>Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa</article-title><source>Acta Trop</source><year>2003</year><volume>86</volume><issue>2&#x02013;3</issue><fpage>125</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0001-706X(03)00029-9</pub-id><?supplied-pmid 12745133?><pub-id pub-id-type="pmid">12745133</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers</source><year>2006</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Summary of global update on preventive chemotherapy implementation in 2015</article-title><source>Wkly Epidemiol Rec</source><year>2016</year><volume>91</volume><issue>39</issue><fpage>456</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">27758092</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;nnert</surname><given-names>R</given-names></name><name><surname>Andrews</surname><given-names>P</given-names></name></person-group><article-title>Praziquantel, a new broad-spectrum antischistosomal agent</article-title><source>Z Parasitenkd</source><year>1977</year><volume>52</volume><issue>2</issue><fpage>129</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/BF00389899</pub-id><?supplied-pmid 410178?><pub-id pub-id-type="pmid">410178</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenhoff</surname><given-names>MJ</given-names></name><name><surname>Cioli</surname><given-names>D</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis</article-title><source>Curr Opin Infect Dis</source><year>2008</year><volume>21</volume><issue>6</issue><fpage>659</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328318978f</pub-id><?supplied-pmid 18978535?><pub-id pub-id-type="pmid">18978535</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A</given-names></name><name><surname>Wegner</surname><given-names>DH</given-names></name></person-group><article-title>Multicentre trials of praziquantel in human schistosomiasis: design and techniques</article-title><source>Bull World Health Organ</source><year>1979</year><volume>57</volume><issue>5</issue><fpage>767</fpage><lpage>71</lpage><?supplied-pmid 317254?><pub-id pub-id-type="pmid">317254</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>M</given-names></name><name><surname>Metwally</surname><given-names>A</given-names></name><name><surname>Farghaly</surname><given-names>A</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>LF</given-names></name><name><surname>Bennett</surname><given-names>JL</given-names></name></person-group><article-title>Characterisation of isolates of <italic>Schistosoma mansoni</italic> from Egyptian villagers that tolerate high doses of praziquantel</article-title><source>Am J Trop Med Hyg</source><year>1996</year><volume>55</volume><fpage>214</fpage><lpage>8</lpage><?supplied-pmid 8780463?><pub-id pub-id-type="pmid">8780463</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallon</surname><given-names>PG</given-names></name><name><surname>Mubarak</surname><given-names>JS</given-names></name><name><surname>Fookes</surname><given-names>RE</given-names></name><name><surname>Niang</surname><given-names>M</given-names></name><name><surname>Butterworth</surname><given-names>AE</given-names></name><name><surname>Sturrock</surname><given-names>RF</given-names></name><name><surname>Doenhoff</surname><given-names>MJ</given-names></name></person-group><article-title><italic>Schistosoma mansoni</italic>: maturation rate and drug susceptibility of different geographic isolates</article-title><source>Exp Parasitol</source><year>1997</year><volume>86</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1006/expr.1997.4149</pub-id><?supplied-pmid 9149238?><pub-id pub-id-type="pmid">9149238</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melman</surname><given-names>SD</given-names></name><name><surname>Steinauer</surname><given-names>ML</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Kubatko</surname><given-names>LS</given-names></name><name><surname>Mwangi</surname><given-names>IN</given-names></name><name><surname>Wynn</surname><given-names>NB</given-names></name><name><surname>Mutuku</surname><given-names>MW</given-names></name><name><surname>Karanja</surname><given-names>DM</given-names></name><name><surname>Colley</surname><given-names>DG</given-names></name><name><surname>Black</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of <italic>Schistosoma mansoni</italic></article-title><source>PLoS Negl Trop Dis</source><year>2009</year><volume>3</volume><issue>8</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0000504</pub-id><?supplied-pmid 19688043?><pub-id pub-id-type="pmid">19688043</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control</article-title><source>Expert Opin Pharmacother</source><year>2004</year><volume>5</volume><issue>2</issue><fpage>263</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1517/14656566.5.2.263</pub-id><?supplied-pmid 14996624?><pub-id pub-id-type="pmid">14996624</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danso-Appiah</surname><given-names>A</given-names></name><name><surname>Olliaro</surname><given-names>PL</given-names></name><name><surname>Donegan</surname><given-names>S</given-names></name><name><surname>Sinclair</surname><given-names>D</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Drugs for treating <italic>Schistosoma mansoni</italic> infection</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>2</volume><fpage>CD000528</fpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danso-Appiah</surname><given-names>A</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name></person-group><article-title>Drugs for treating urinary schistosomiasis</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>3</volume></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekhar</surname><given-names>KC</given-names></name></person-group><article-title>Schistosomiasis drug therapy and treatment considerations</article-title><source>Drugs</source><year>1991</year><volume>42</volume><issue>3</issue><fpage>379</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.2165/00003495-199142030-00004</pub-id><?supplied-pmid 1720380?><pub-id pub-id-type="pmid">1720380</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>SL</given-names></name><name><surname>Ingram</surname><given-names>KJ</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Diagnosis and treatment of schistosomiasis in children in the era of intensified control</article-title><source>Expert Rev Anti Infect Ther</source><year>2013</year><volume>11</volume><issue>11</issue><fpage>1237</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1586/14787210.2013.844066</pub-id><?supplied-pmid 24127662?><pub-id pub-id-type="pmid">24127662</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollinson</surname><given-names>D</given-names></name><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Levitz</surname><given-names>S</given-names></name><name><surname>Stothard</surname><given-names>JR</given-names></name><name><surname>Tchuem Tchuent&#x000e9;</surname><given-names>LA</given-names></name><name><surname>Garba</surname><given-names>A</given-names></name><name><surname>Mohammed</surname><given-names>KA</given-names></name><name><surname>Schur</surname><given-names>N</given-names></name><name><surname>Person</surname><given-names>B</given-names></name><name><surname>Colley</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Time to set the agenda for schistosomiasis elimination</article-title><source>Acta Trop</source><year>2013</year><volume>128</volume><issue>2</issue><fpage>423</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2012.04.013</pub-id><?supplied-pmid 22580511?><pub-id pub-id-type="pmid">22580511</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation</source><year>2012</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>JET</given-names></name><name><surname>Croll</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>WE</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>MC</given-names></name><name><surname>Templeton</surname><given-names>MR</given-names></name></person-group><article-title>The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0003296</pub-id><?supplied-pmid 25474705?><pub-id pub-id-type="pmid">25474705</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokolow</surname><given-names>SH</given-names></name><name><surname>Wood</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>IJ</given-names></name><name><surname>Swartz</surname><given-names>SJ</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>MH</given-names></name><name><surname>Lafferty</surname><given-names>KD</given-names></name><name><surname>Kuris</surname><given-names>AM</given-names></name><name><surname>Rickards</surname><given-names>C</given-names></name><name><surname>De Leo</surname><given-names>GA</given-names></name></person-group><article-title>Global assessment of schistosomiasis control over the past century shows targeting the snail intermediate host works best</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0004794</pub-id><?supplied-pmid 27441556?><pub-id pub-id-type="pmid">27441556</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>The drugs we have and the drugs we need against major helminth infections</article-title><source>Adv Parasitol</source><year>2010</year><volume>73</volume><fpage>197</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(10)73008-6</pub-id><?supplied-pmid 20627144?><pub-id pub-id-type="pmid">20627144</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrique</surname><given-names>B</given-names></name><name><surname>Strub-Wourgaft</surname><given-names>N</given-names></name><name><surname>Some</surname><given-names>C</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Trouiller</surname><given-names>P</given-names></name><name><surname>Ford</surname><given-names>N</given-names></name><name><surname>P&#x000e9;coul</surname><given-names>B</given-names></name><name><surname>Bradol</surname><given-names>J-H</given-names></name></person-group><article-title>The drug and vaccine landscape for neglected diseases (2000&#x02013;11): a systematic assessment</article-title><source>Lancet Glob Health</source><year>2013</year><volume>1</volume><issue>6</issue><fpage>371</fpage><lpage>e379</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(13)70078-0</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerts</surname><given-names>S</given-names></name><name><surname>Gryseels</surname><given-names>B</given-names></name></person-group><article-title>Drug resistance in human helminths: current situation and lessons from livestock</article-title><source>Clin Microbiol Rev</source><year>2000</year><volume>13</volume><issue>2</issue><fpage>207</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1128/CMR.13.2.207-222.2000</pub-id><?supplied-pmid 10755998?><pub-id pub-id-type="pmid">10755998</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodrow</surname><given-names>CJ</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread</article-title><source>FEMS Microbiol Rev</source><year>2017</year><volume>41</volume><issue>1</issue><fpage>34</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuw037</pub-id><?supplied-pmid 27613271?><pub-id pub-id-type="pmid">27613271</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>In vitro and in vivo trematode models for chemotherapeutic studies</article-title><source>Parasitology</source><year>2010</year><volume>137</volume><issue>3</issue><fpage>589</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1017/S0031182009991739</pub-id><?supplied-pmid 19961653?><pub-id pub-id-type="pmid">19961653</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagboto</surname><given-names>S</given-names></name><name><surname>Townson</surname><given-names>S</given-names></name></person-group><article-title>Antiparasitic properties of medicinal plants and other naturally occurring products</article-title><source>Adv Parasitol</source><year>2001</year><volume>50</volume><fpage>199</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(01)50032-9</pub-id><?supplied-pmid 11757332?><pub-id pub-id-type="pmid">11757332</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wink</surname><given-names>M</given-names></name></person-group><article-title>Medicinal plants: a source of anti-parasitic secondary metabolites</article-title><source>Molecules</source><year>2012</year><volume>17</volume><issue>11</issue><fpage>12771</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3390/molecules171112771</pub-id><?supplied-pmid 23114614?><pub-id pub-id-type="pmid">23114614</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marston</surname><given-names>A</given-names></name><name><surname>Maillard</surname><given-names>M</given-names></name><name><surname>Hostettmann</surname><given-names>K</given-names></name></person-group><article-title>Search for antifungal, molluscicidal and larvicidal compounds from African medicinal plants</article-title><source>J Ethnopharmacol</source><year>1993</year><volume>38</volume><issue>2&#x02013;3</issue><fpage>215</fpage><lpage>23</lpage><?supplied-pmid 8510471?><pub-id pub-id-type="pmid">8510471</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spivak</surname><given-names>AY</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Gubaidullin</surname><given-names>RR</given-names></name><name><surname>Nedopekina</surname><given-names>DA</given-names></name><name><surname>Shakurova</surname><given-names>ER</given-names></name><name><surname>Khalitova</surname><given-names>RR</given-names></name><name><surname>Odinokov</surname><given-names>VN</given-names></name></person-group><article-title>Synthesis and activity of new triphenylphosphonium derivatives of betulin and betulinic acid against <italic>Schistosoma mansoni</italic> in vitro and in vivo</article-title><source>Bioorg Med Chem</source><year>2014</year><volume>22</volume><issue>21</issue><fpage>6297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2014.07.014</pub-id><?supplied-pmid 25245671?><pub-id pub-id-type="pmid">25245671</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Moraes</surname><given-names>J</given-names></name></person-group><article-title>Natural products with antischistosomal activity</article-title><source>Future Med Chem</source><year>2015</year><volume>7</volume><issue>6</issue><fpage>801</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.4155/fmc.15.23</pub-id><?supplied-pmid 25996071?><pub-id pub-id-type="pmid">25996071</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>BJ</given-names></name><name><surname>Andrade</surname><given-names>CH</given-names></name><name><surname>Cravo</surname><given-names>PV</given-names></name></person-group><article-title>Natural products as leads in schistosome drug discovery</article-title><source>Molecules</source><year>2015</year><volume>20</volume><issue>2</issue><fpage>1872</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.3390/molecules20021872</pub-id><?supplied-pmid 25625682?><pub-id pub-id-type="pmid">25625682</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driguez</surname><given-names>P</given-names></name><name><surname>McManus</surname><given-names>DP</given-names></name><name><surname>Gobert</surname><given-names>GN</given-names></name></person-group><article-title>Clinical implications of recent findings in schistosome proteomics</article-title><source>Expert Rev Proteomics</source><year>2016</year><volume>13</volume><issue>1</issue><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1586/14789450.2016.1116390</pub-id><?supplied-pmid 26558506?><pub-id pub-id-type="pmid">26558506</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>BJ</given-names></name><name><surname>LoVerde</surname><given-names>PT</given-names></name><name><surname>Wilson</surname><given-names>RA</given-names></name><name><surname>Dillon</surname><given-names>GP</given-names></name><name><surname>Cerqueira</surname><given-names>GC</given-names></name><name><surname>Mashiyama</surname><given-names>ST</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name><name><surname>Andrade</surname><given-names>LF</given-names></name><name><surname>Ashton</surname><given-names>PD</given-names></name><etal/></person-group><article-title>The genome of the blood fluke <italic>Schistosoma mansoni</italic></article-title><source>Nature</source><year>2009</year><volume>460</volume><issue>7253</issue><fpage>352</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature08160</pub-id><?supplied-pmid 19606141?><pub-id pub-id-type="pmid">19606141</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>ND</given-names></name><name><surname>Jex</surname><given-names>AR</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cantacessi</surname><given-names>C</given-names></name><name><surname>Hall</surname><given-names>RS</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Whole-genome sequence of <italic>Schistosoma haematobium</italic></article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><issue>2</issue><fpage>221</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/ng.1065</pub-id><?supplied-pmid 22246508?><pub-id pub-id-type="pmid">22246508</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>LG</given-names></name><name><surname>Oliva</surname><given-names>G</given-names></name><name><surname>Andricopulo</surname><given-names>AD</given-names></name></person-group><article-title>Target-based molecular modeling strategies for schistosomiasis drug discovery</article-title><source>Future Med Chem</source><year>2015</year><volume>7</volume><issue>6</issue><fpage>753</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.4155/fmc.15.21</pub-id><?supplied-pmid 25996068?><pub-id pub-id-type="pmid">25996068</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>JP</given-names></name><name><surname>Oliviera</surname><given-names>G</given-names></name><name><surname>Rollinson</surname><given-names>D</given-names></name><name><surname>Gower</surname><given-names>CM</given-names></name></person-group><article-title>Schistosome genomes: a wealth of information</article-title><source>Trends Parasitol</source><year>2010</year><volume>26</volume><issue>3</issue><fpage>103</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2009.12.006</pub-id><?supplied-pmid 20083437?><pub-id pub-id-type="pmid">20083437</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Antimalarials in the treatment of schistosomiasis</article-title><source>Curr Pharm Des</source><year>2012</year><volume>18</volume><issue>24</issue><fpage>3531</fpage><lpage>8</lpage><?supplied-pmid 22607145?><pub-id pub-id-type="pmid">22607145</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panic</surname><given-names>G</given-names></name><name><surname>Duthaler</surname><given-names>U</given-names></name><name><surname>Speich</surname><given-names>B</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Repurposing drugs for the treatment and control of helminth infections</article-title><source>Int J Parasitol Drugs Drug Resist</source><year>2014</year><volume>4</volume><issue>3</issue><fpage>185</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2014.07.002</pub-id><?supplied-pmid 25516827?><pub-id pub-id-type="pmid">25516827</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullner</surname><given-names>A</given-names></name><name><surname>Helfer</surname><given-names>A</given-names></name><name><surname>Kotlyar</surname><given-names>D</given-names></name><name><surname>Oswald</surname><given-names>J</given-names></name><name><surname>Efferth</surname><given-names>T</given-names></name></person-group><article-title>Chemistry and pharmacology of neglected helminthic diseases</article-title><source>Curr Med Chem</source><year>2011</year><volume>18</volume><issue>5</issue><fpage>767</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2174/092986711794480096</pub-id><?supplied-pmid 21182483?><pub-id pub-id-type="pmid">21182483</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Catto</surname><given-names>BA</given-names></name></person-group><article-title>In vitro and in vivo studies of the effect of artemether on <italic>Schistosoma mansoni</italic></article-title><source>Antimicrob Agents Chemother</source><year>1989</year><volume>33</volume><issue>9</issue><fpage>1557</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.9.1557</pub-id><?supplied-pmid 2510595?><pub-id pub-id-type="pmid">2510595</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>ZW</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Comparative study of the effects of artemether and artesunate on juvenile and adult <italic>Schistosoma mansoni</italic> in experimentally infected mice</article-title><source>Trans R Soc Trop Med Hyg</source><year>2002</year><volume>96</volume><issue>3</issue><fpage>318</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/S0035-9203(02)90110-0</pub-id><?supplied-pmid 12174787?><pub-id pub-id-type="pmid">12174787</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>B</given-names></name></person-group><article-title>Hybrid molecules with a dual mode of action: dream or reality?</article-title><source>Acc Chem Res</source><year>2008</year><volume>41</volume><issue>1</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1021/ar7000843</pub-id><?supplied-pmid 17665872?><pub-id pub-id-type="pmid">17665872</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boissier</surname><given-names>J</given-names></name><name><surname>Cosledan</surname><given-names>F</given-names></name><name><surname>Robert</surname><given-names>A</given-names></name><name><surname>Meunier</surname><given-names>B</given-names></name></person-group><article-title>In vitro activities of trioxaquines against <italic>Schistosoma mansoni</italic></article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><issue>11</issue><fpage>4903</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1128/AAC.00640-09</pub-id><?supplied-pmid 19596887?><pub-id pub-id-type="pmid">19596887</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradines</surname><given-names>V</given-names></name><name><surname>Portela</surname><given-names>J</given-names></name><name><surname>Boissier</surname><given-names>J</given-names></name><name><surname>Cosledan</surname><given-names>F</given-names></name><name><surname>Meunier</surname><given-names>B</given-names></name><name><surname>Robert</surname><given-names>A</given-names></name></person-group><article-title>Trioxaquine PA1259 alkylates heme in the blood-feeding parasite <italic>Schistosoma mansoni</italic></article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>5</issue><fpage>2403</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1128/AAC.00082-11</pub-id><?supplied-pmid 21300841?><pub-id pub-id-type="pmid">21300841</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Vennerstrom</surname><given-names>JL</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>The in vitro and in vivo activities of synthetic trioxolanes on major human schistosome species</article-title><source>Antimicrobial Agents Chemother</source><year>2007</year><volume>51</volume><issue>4</issue><fpage>1440</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1128/AAC.01537-06</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Artemisinins and synthetic trioxolanes in the treatment of helminth infections</article-title><source>Curr Opin Infect Dis</source><year>2007</year><volume>20</volume><issue>6</issue><fpage>605</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e3282f19ec4</pub-id><?supplied-pmid 17975411?><pub-id pub-id-type="pmid">17975411</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Ingram</surname><given-names>K</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Vennerstrom</surname><given-names>JL</given-names></name></person-group><article-title>In vivo activity of aryl ozonides against <italic>Schistosoma</italic> species</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><issue>2</issue><fpage>1090</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1128/AAC.05371-11</pub-id><?supplied-pmid 22106214?><pub-id pub-id-type="pmid">22106214</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidova</surname><given-names>A</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics of the antischistosomal lead ozonide OZ418 in uninfected mice determined by liquid chromatography-tandem mass spectrometry</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>12</issue><fpage>7364</fpage><lpage>71</lpage><?supplied-pmid 27697760?><pub-id pub-id-type="pmid">27697760</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossallam</surname><given-names>SF</given-names></name><name><surname>Amer</surname><given-names>EI</given-names></name><name><surname>El-Faham</surname><given-names>MH</given-names></name></person-group><article-title>Efficacy of Synriam, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of <italic>Schistosoma mansoni</italic></article-title><source>Acta Trop</source><year>2015</year><volume>143</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2014.12.005</pub-id><?supplied-pmid 25530543?><pub-id pub-id-type="pmid">25530543</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>N</given-names></name><name><surname>Yaremenko</surname><given-names>IA</given-names></name><name><surname>Krylov</surname><given-names>IB</given-names></name><name><surname>Terent&#x02019;ev</surname><given-names>AO</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine derivatives against <italic>Schistosoma mansoni</italic></article-title><source>Bioorg Med Chem</source><year>2015</year><volume>23</volume><issue>16</issue><fpage>5175</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.02.010</pub-id><?supplied-pmid 25744189?><pub-id pub-id-type="pmid">25744189</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Nassauw</surname><given-names>L</given-names></name><name><surname>Toovey</surname><given-names>S</given-names></name><name><surname>Van Op den bosch</surname><given-names>J</given-names></name><name><surname>Timmermans</surname><given-names>J-P</given-names></name><name><surname>Vercruysse</surname><given-names>J</given-names></name></person-group><article-title>Schistosomicidal activity of the antimalarial drug, mefloquine, in <italic>Schistosoma mansoni</italic>-infected mice</article-title><source>Travel Med Infect Dis</source><year>2008</year><volume>6</volume><issue>5</issue><fpage>253</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2008.06.006</pub-id><?supplied-pmid 18760248?><pub-id pub-id-type="pmid">18760248</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlagenhauf</surname><given-names>P</given-names></name><name><surname>Adamcova</surname><given-names>M</given-names></name><name><surname>Regep</surname><given-names>L</given-names></name><name><surname>Schaerer</surname><given-names>MT</given-names></name><name><surname>Rhein</surname><given-names>HG</given-names></name></person-group><article-title>The position of mefloquine as a 21st century malaria chemoprophylaxis</article-title><source>Malar J</source><year>2010</year><volume>9</volume><fpage>357</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-9-357</pub-id><?supplied-pmid 21143906?><pub-id pub-id-type="pmid">21143906</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Mei</surname><given-names>JY</given-names></name><name><surname>Jiao</surname><given-names>PY</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Mefloquine-an aminoalcohol with promising antischistosomal properties in mice</article-title><source>PLoS Negl Trop Dis</source><year>2009</year><volume>3</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0000350</pub-id><?supplied-pmid 19125172?><pub-id pub-id-type="pmid">19125172</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manneck</surname><given-names>T</given-names></name><name><surname>Braissant</surname><given-names>O</given-names></name><name><surname>Ellis</surname><given-names>W</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title><italic>Schistosoma mansoni</italic>: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo</article-title><source>Exp Parasitol</source><year>2011</year><volume>127</volume><issue>1</issue><fpage>260</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2010.08.011</pub-id><?supplied-pmid 20732321?><pub-id pub-id-type="pmid">20732321</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Shady</surname><given-names>OM</given-names></name><name><surname>Mohammed</surname><given-names>SS</given-names></name><name><surname>Attia</surname><given-names>SS</given-names></name><name><surname>Yusuf</surname><given-names>HA</given-names></name><name><surname>Helmy</surname><given-names>DO</given-names></name></person-group><article-title>Therapeutic effect of mefloquine on <italic>Schistosoma mansoni</italic> in experimental infection in mice</article-title><source>J Parasit Dis</source><year>2016</year><volume>40</volume><issue>2</issue><fpage>259</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s12639-014-0489-4</pub-id><?supplied-pmid 27413290?><pub-id pub-id-type="pmid">27413290</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>JY</given-names></name><name><surname>Jiao</surname><given-names>PY</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Effect of single-dose oral mefloquine on the morphology of adult <italic>Schistosoma japonicum</italic> in mice</article-title><source>Parasitol Res</source><year>2009</year><volume>105</volume><issue>3</issue><fpage>853</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s00436-009-1471-4</pub-id><?supplied-pmid 19458964?><pub-id pub-id-type="pmid">19458964</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>W</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Antischistosomal activities of mefloquine-related arylmethanols</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><issue>6</issue><fpage>3207</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1128/AAC.06177-11</pub-id><?supplied-pmid 22470113?><pub-id pub-id-type="pmid">22470113</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Manneck</surname><given-names>T</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name></person-group><article-title>Interactions of mefloquine with praziquantel in the <italic>Schistosoma mansoni</italic> mouse model and in vitro</article-title><source>J Antimicrob Chemother</source><year>2011</year><volume>66</volume><issue>8</issue><fpage>1791</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr178</pub-id><?supplied-pmid 21602552?><pub-id pub-id-type="pmid">21602552</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram-Sieber</surname><given-names>K</given-names></name><name><surname>Cowan</surname><given-names>N</given-names></name><name><surname>Panic</surname><given-names>G</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Mansour</surname><given-names>NR</given-names></name><name><surname>Bickle</surname><given-names>QD</given-names></name><name><surname>Wells</surname><given-names>TN</given-names></name><name><surname>Spangenberg</surname><given-names>T</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Orally active antischistosomal early leads identified from the open access malaria box</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0002610</pub-id><?supplied-pmid 24416463?><pub-id pub-id-type="pmid">24416463</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>N</given-names></name><name><surname>Datwyler</surname><given-names>P</given-names></name><name><surname>Ernst</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Vennerstrom</surname><given-names>JL</given-names></name><name><surname>Spangenberg</surname><given-names>T</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Activities of N, N&#x02019;-Diarylurea MMV665852 analogs against <italic>Schistosoma mansoni</italic></article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>4</issue><fpage>1935</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1128/AAC.04463-14</pub-id><?supplied-pmid 25583726?><pub-id pub-id-type="pmid">25583726</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Rubbiani</surname><given-names>R</given-names></name><name><surname>Gasser</surname><given-names>G</given-names></name><name><surname>Biot</surname><given-names>C</given-names></name></person-group><article-title>In vitro and in vivo antischistosomal activity of ferroquine derivatives</article-title><source>Parasit Vectors</source><year>2014</year><volume>7</volume><fpage>424</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-7-424</pub-id><?supplied-pmid 25190030?><pub-id pub-id-type="pmid">25190030</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MO</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Amoyaw</surname><given-names>PN</given-names></name><name><surname>Hossain</surname><given-names>MF</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Le</surname><given-names>JG</given-names></name><name><surname>Simpson</surname><given-names>NC</given-names></name><name><surname>Roewe</surname><given-names>KD</given-names></name><name><surname>Freeman</surname><given-names>TN</given-names></name><name><surname>Hasley</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Discovery of antischistosomal drug leads based on tetraazamacrocyclic derivatives and their metal complexes</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>9</issue><fpage>5331</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1128/AAC.00778-16</pub-id><?supplied-pmid 27324765?><pub-id pub-id-type="pmid">27324765</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eissa</surname><given-names>MM</given-names></name><name><surname>El-Azzouni</surname><given-names>MZ</given-names></name><name><surname>Amer</surname><given-names>EI</given-names></name><name><surname>Baddour</surname><given-names>NM</given-names></name></person-group><article-title>Miltefosine, a promising novel agent for schistosomiasis mansoni</article-title><source>Int J Parasitol</source><year>2011</year><volume>41</volume><issue>2</issue><fpage>235</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2010.09.010</pub-id><?supplied-pmid 21055404?><pub-id pub-id-type="pmid">21055404</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Moslemany</surname><given-names>RM</given-names></name><name><surname>Eissa</surname><given-names>MM</given-names></name><name><surname>Ramadan</surname><given-names>AA</given-names></name><name><surname>El-Khordagui</surname><given-names>LK</given-names></name><name><surname>El-Azzouni</surname><given-names>MZ</given-names></name></person-group><article-title>Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni</article-title><source>Acta Trop</source><year>2016</year><volume>159</volume><fpage>142</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.03.038</pub-id><?supplied-pmid 27039667?><pub-id pub-id-type="pmid">27039667</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eissa</surname><given-names>MM</given-names></name><name><surname>Mossallam</surname><given-names>SF</given-names></name><name><surname>Amer</surname><given-names>EI</given-names></name><name><surname>Younis</surname><given-names>LK</given-names></name><name><surname>Rashed</surname><given-names>HA</given-names></name></person-group><article-title>Repositioning of chlorambucil as a potential anti-schistosomal agent</article-title><source>Acta Trop</source><year>2016</year><volume>166</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.11.006</pub-id><?supplied-pmid 27836498?><pub-id pub-id-type="pmid">27836498</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>N</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Repurposing of anticancer drugs: in vitro and in vivo activities against <italic>Schistosoma mansoni</italic></article-title><source>Parasit Vectors</source><year>2015</year><volume>8</volume><fpage>417</fpage><pub-id pub-id-type="doi">10.1186/s13071-015-1023-y</pub-id><?supplied-pmid 26265386?><pub-id pub-id-type="pmid">26265386</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelmedin</surname><given-names>V</given-names></name><name><surname>Dissous</surname><given-names>C</given-names></name><name><surname>Grevelding</surname><given-names>CG</given-names></name></person-group><article-title>Re-positioning protein-kinase inhibitors against schistosomiasis</article-title><source>Future Med Chem</source><year>2015</year><volume>7</volume><issue>6</issue><fpage>737</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.4155/fmc.15.31</pub-id><?supplied-pmid 25996067?><pub-id pub-id-type="pmid">25996067</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Panic</surname><given-names>G</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Gautam</surname><given-names>N</given-names></name><name><surname>Vennerstrom</surname><given-names>JL</given-names></name></person-group><article-title>Aryl hydantoin Ro 13&#x02013;3978, a broad-spectrum antischistosomal</article-title><source>J Antimicrob Chemother</source><year>2015</year><volume>70</volume><issue>6</issue><fpage>1788</fpage><lpage>97</lpage><?supplied-pmid 25691324?><pub-id pub-id-type="pmid">25691324</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Vennerstrom</surname><given-names>JL</given-names></name></person-group><article-title>Activity of antiandrogens against juvenile and adult <italic>Schistosoma mansoni</italic> in mice</article-title><source>J Antimicrob Chemother</source><year>2010</year><volume>65</volume><issue>9</issue><fpage>1991</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq233</pub-id><?supplied-pmid 20576641?><pub-id pub-id-type="pmid">20576641</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>JO</given-names></name><name><surname>White</surname><given-names>KL</given-names></name><name><surname>Shackleford</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Saunders</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>AC</given-names></name><name><surname>Chiu</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Revisiting the SAR of the antischistosomal aryl hydantoin (Ro 13&#x02013;3978)</article-title><source>J Med Chem</source><year>2016</year><volume>59</volume><issue>23</issue><fpage>10705</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01410</pub-id><?supplied-pmid 27933964?><pub-id pub-id-type="pmid">27933964</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidi</surname><given-names>A</given-names></name><name><surname>Lalli</surname><given-names>C</given-names></name><name><surname>Perlas</surname><given-names>E</given-names></name><name><surname>Bolasco</surname><given-names>G</given-names></name><name><surname>Nibbio</surname><given-names>M</given-names></name><name><surname>Monteagudo</surname><given-names>E</given-names></name><name><surname>Bresciani</surname><given-names>A</given-names></name><name><surname>Ruberti</surname><given-names>G</given-names></name></person-group><article-title>Discovery and characterization of novel anti-schistosomal properties of the anti-anginal drug, perhexiline and its impact on <italic>Schistosoma mansoni</italic> male and female reproductive systems</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>8</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0004928</pub-id><?supplied-pmid 27518281?><pub-id pub-id-type="pmid">27518281</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panic</surname><given-names>G</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Scandale</surname><given-names>I</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Activity profile of an FDA-approved compound library against <italic>Schistosoma mansoni</italic></article-title><source>PLoS Negl Trop Dis</source><year>2015</year><volume>9</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0003962</pub-id><?supplied-pmid 26230921?><pub-id pub-id-type="pmid">26230921</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulla</surname><given-names>MH</given-names></name><name><surname>Ruelas</surname><given-names>DS</given-names></name><name><surname>Wolff</surname><given-names>B</given-names></name><name><surname>Snedecor</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>KC</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>McKerrow</surname><given-names>JH</given-names></name><name><surname>Caffrey</surname><given-names>CR</given-names></name></person-group><article-title>Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening</article-title><source>PLoS Negl Trop Dis</source><year>2009</year><volume>3</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0000478</pub-id><?supplied-pmid 19597541?><pub-id pub-id-type="pmid">19597541</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>MG</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites</article-title><source>Curr Med Chem</source><year>2001</year><volume>8</volume><issue>15</issue><fpage>1841</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.2174/0929867013371581</pub-id><?supplied-pmid 11772354?><pub-id pub-id-type="pmid">11772354</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Artemisinins for schistosomiasis and beyond</article-title><source>Curr Opin Investig Drugs</source><year>2007</year><volume>8</volume><issue>2</issue><fpage>105</fpage><lpage>16</lpage><?supplied-pmid 17328226?><pub-id pub-id-type="pmid">17328226</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>ACTs for schistosomiasis: do they act?</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><issue>9</issue><fpage>579</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70169-9</pub-id><?supplied-pmid 20705514?><pub-id pub-id-type="pmid">20705514</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>MG</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name></person-group><article-title>Research and development of antischistosomal drugs in the People&#x02019;s Republic of China: a 60-year review</article-title><source>Adv Parasitol</source><year>2010</year><volume>73</volume><fpage>231</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0065-308X(10)73009-8</pub-id><?supplied-pmid 20627145?><pub-id pub-id-type="pmid">20627145</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez del Villar</surname><given-names>L</given-names></name><name><surname>Burguillo</surname><given-names>FJ</given-names></name><name><surname>Lopez-Aban</surname><given-names>J</given-names></name><name><surname>Muro</surname><given-names>A</given-names></name></person-group><article-title>Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><fpage>e45867</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0045867</pub-id><?supplied-pmid 23029285?><pub-id pub-id-type="pmid">23029285</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>ME</given-names></name><name><surname>Krishna</surname><given-names>S</given-names></name><name><surname>Greten</surname><given-names>HJ</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Efferth</surname><given-names>T</given-names></name></person-group><article-title>Antischistosomal activity of artemisinin derivatives in vivo and in patients</article-title><source>Pharmacol Res</source><year>2016</year><volume>110</volume><fpage>216</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.02.017</pub-id><?supplied-pmid 26902577?><pub-id pub-id-type="pmid">26902577</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Qinghaosu (artemisinin): the price of success</article-title><source>Science</source><year>2008</year><volume>320</volume><issue>5874</issue><fpage>330</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1126/science.1155165</pub-id><?supplied-pmid 18420924?><pub-id pub-id-type="pmid">18420924</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tambo</surname><given-names>E</given-names></name><name><surname>Khater</surname><given-names>EI</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Bergquist</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>XN</given-names></name></person-group><article-title>Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty</article-title><source>Infect Dis Poverty</source><year>2015</year><volume>4</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s40249-015-0091-8</pub-id><?supplied-pmid 26708575?><pub-id pub-id-type="pmid">26708575</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LJ</given-names></name><name><surname>Yang</surname><given-names>HZ</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><article-title>Histological and histochemical changes of <italic>Schistosoma japonicum</italic> and host liver caused by artemether</article-title><source>Acta Pharmaceut Sin</source><year>1983</year><volume>18</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Endriss</surname><given-names>Y</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Effect of artemether against <italic>Schistosoma haematobium</italic> in experimentally infected hamsters</article-title><source>Int J Parasitol</source><year>2000</year><volume>30</volume><issue>9</issue><fpage>1001</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0020-7519(00)00091-6</pub-id><?supplied-pmid 10980290?><pub-id pub-id-type="pmid">10980290</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>N&#x02019;Dri</surname><given-names>A</given-names></name><name><surname>Lengeler</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Oral artemether for prevention of <italic>Schistosoma mansoni</italic> infection: randomised controlled trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><issue>9212</issue><fpage>1320</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02114-0</pub-id><?supplied-pmid 10776745?><pub-id pub-id-type="pmid">10776745</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Gnaka</surname><given-names>HN</given-names></name><name><surname>Yapi</surname><given-names>A</given-names></name><name><surname>N&#x02019;Guessan</surname><given-names>NA</given-names></name><name><surname>Kigbafori</surname><given-names>SD</given-names></name><name><surname>Lengeler</surname><given-names>C</given-names></name><name><surname>Chollet</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>SH</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name></person-group><article-title>Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent <italic>Schistosoma haematobium</italic> infections</article-title><source>Am J Trop Med Hyg</source><year>2003</year><volume>68</volume><issue>1</issue><fpage>24</fpage><lpage>32</lpage><?supplied-pmid 12556143?><pub-id pub-id-type="pmid">12556143</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrmann</surname><given-names>S</given-names></name><name><surname>Szlez&#x000e1;k</surname><given-names>N</given-names></name><name><surname>Faucher</surname><given-names>J-F</given-names></name><name><surname>Matsiegui</surname><given-names>P-B</given-names></name><name><surname>Neubauer</surname><given-names>R</given-names></name><name><surname>Binder</surname><given-names>RK</given-names></name><name><surname>Lell</surname><given-names>B</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name></person-group><article-title>Artesunate and praziquantel for the treatment of <italic>Schistosoma haematobium</italic> infections: a double-blind, randomized, placebo-controlled study</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><issue>10</issue><fpage>1363</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1086/324004</pub-id><?supplied-pmid 11679932?><pub-id pub-id-type="pmid">11679932</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>C</given-names></name><name><surname>Henrich</surname><given-names>PP</given-names></name><name><surname>Passi</surname><given-names>N</given-names></name><name><surname>Fidock</surname><given-names>DA</given-names></name></person-group><article-title>Recent clinical and molecular insights into emerging artemisinin resistance in <italic>Plasmodium falciparum</italic></article-title><source>Curr Opin Infect Dis</source><year>2011</year><volume>24</volume><issue>6</issue><fpage>570</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e32834cd3ed</pub-id><?supplied-pmid 22001944?><pub-id pub-id-type="pmid">22001944</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SM</given-names></name><name><surname>Juliano</surname><given-names>JJ</given-names></name></person-group><article-title>Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot</article-title><source>J Infect Dis</source><year>2014</year><volume>210</volume><issue>3</issue><fpage>335</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu142</pub-id><?supplied-pmid 24610873?><pub-id pub-id-type="pmid">24610873</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmorshedy</surname><given-names>H</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Bergquist</surname><given-names>RN</given-names></name><name><surname>Sharaf</surname><given-names>S</given-names></name><name><surname>Barakat</surname><given-names>R</given-names></name></person-group><article-title>Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: a randomized controlled trial</article-title><source>Acta Trop</source><year>2016</year><volume>158</volume><fpage>52</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2016.02.015</pub-id><?supplied-pmid 26921676?><pub-id pub-id-type="pmid">26921676</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>C</given-names></name><name><surname>Katare</surname><given-names>S</given-names></name><name><surname>Baig</surname><given-names>M</given-names></name><name><surname>Doifode</surname><given-names>S</given-names></name></person-group><article-title>Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapy</article-title><source>Ann Med Health Sci Res</source><year>2014</year><volume>4</volume><issue>4</issue><fpage>466</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.4103/2141-9248.139270</pub-id><?supplied-pmid 25221689?><pub-id pub-id-type="pmid">25221689</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barda</surname><given-names>B</given-names></name><name><surname>Coulibaly</surname><given-names>JT</given-names></name><name><surname>Puchkov</surname><given-names>M</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Hattendorf</surname><given-names>J</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and safety of moxidectin, Synriam, Synriam-praziquantel versus praziquantel against <italic>Schistosoma haematobium</italic> and <italic>S. mansoni</italic> infections: a randomized, exploratory phase 2 trial</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>9</issue><fpage>e0005008</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0005008</pub-id><?supplied-pmid 27636542?><pub-id pub-id-type="pmid">27636542</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>N&#x02019;Guessan</surname><given-names>NA</given-names></name><name><surname>Adoubryn</surname><given-names>KD</given-names></name><name><surname>Silu&#x000e9;</surname><given-names>KD</given-names></name><name><surname>Vounatsou</surname><given-names>P</given-names></name><name><surname>Hatz</surname><given-names>C</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name></person-group><article-title>Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against <italic>Schistosoma haematobium</italic>: randomized, exploratory open-label trial</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><issue>9</issue><fpage>1205</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1086/651682</pub-id><?supplied-pmid 20350194?><pub-id pub-id-type="pmid">20350194</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>J</given-names></name><name><surname>Silu&#x000e9;</surname><given-names>KD</given-names></name><name><surname>Adiossan</surname><given-names>LK</given-names></name><name><surname>N&#x02019;Guessan</surname><given-names>NA</given-names></name><name><surname>Monsan</surname><given-names>N</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name></person-group><article-title>Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against <italic>Schistosoma haematobium</italic>: a randomized, exploratory, open-label trial</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>7</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0002975</pub-id><?supplied-pmid 25033291?><pub-id pub-id-type="pmid">25033291</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genchi</surname><given-names>C</given-names></name><name><surname>Poglayen</surname><given-names>G</given-names></name><name><surname>Kramer</surname><given-names>LH</given-names></name><name><surname>Venco</surname><given-names>L</given-names></name><name><surname>Agostini</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of moxidectin for the prevention of adult heartworm (<italic>Dirofilaria immitis</italic>) infection in dogs</article-title><source>Parassitologia</source><year>2001</year><volume>43</volume><issue>3</issue><fpage>139</fpage><lpage>41</lpage><?supplied-pmid 11921542?><pub-id pub-id-type="pmid">11921542</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awadzi</surname><given-names>K</given-names></name><name><surname>Opoku</surname><given-names>NO</given-names></name><name><surname>Attah</surname><given-names>SK</given-names></name><name><surname>Lazdins-Helds</surname><given-names>J</given-names></name><name><surname>Kuesel</surname><given-names>AC</given-names></name></person-group><article-title>A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in <italic>Onchocerca volvulus</italic> infection</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>6</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0002953</pub-id><?supplied-pmid 24968000?><pub-id pub-id-type="pmid">24968000</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selim</surname><given-names>S</given-names></name><name><surname>El Sagheer</surname><given-names>O</given-names></name><name><surname>El Amir</surname><given-names>A</given-names></name><name><surname>Barakat</surname><given-names>R</given-names></name><name><surname>Hadley</surname><given-names>K</given-names></name><name><surname>Bruins</surname><given-names>MJ</given-names></name><name><surname>El Ridi</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and safety of arachidonic acid for treatment of <italic>Schistosoma mansoni</italic>-infected children in Menoufiya, Egypt</article-title><source>Am J Trop Med Hyg</source><year>2014</year><volume>91</volume><issue>5</issue><fpage>973</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.14-0328</pub-id><?supplied-pmid 25246692?><pub-id pub-id-type="pmid">25246692</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barakat</surname><given-names>R</given-names></name><name><surname>Abou El-Ela</surname><given-names>NE</given-names></name><name><surname>Sharaf</surname><given-names>S</given-names></name><name><surname>El Sagheer</surname><given-names>O</given-names></name><name><surname>Selim</surname><given-names>S</given-names></name><name><surname>Tallima</surname><given-names>H</given-names></name><name><surname>Bruins</surname><given-names>MJ</given-names></name><name><surname>Hadley</surname><given-names>KB</given-names></name><name><surname>El Ridi</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and safety of arachidonic acid for treatment of school-age children in <italic>Schistosoma mansoni</italic> high-endemicity regions</article-title><source>Am J Trop Med Hyg</source><year>2015</year><volume>92</volume><issue>4</issue><fpage>797</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.14-0675</pub-id><?supplied-pmid 25624403?><pub-id pub-id-type="pmid">25624403</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>A</given-names></name><name><surname>Savioli</surname><given-names>L</given-names></name><name><surname>Engels</surname><given-names>D</given-names></name><name><surname>Bergquist</surname><given-names>NR</given-names></name><name><surname>Todd</surname><given-names>MH</given-names></name></person-group><article-title>Drugs for the control of parasitic diseases: current status and development in schistosomiasis</article-title><source>Trends Parasitol</source><year>2003</year><volume>19</volume><issue>11</issue><fpage>509</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2003.09.005</pub-id><?supplied-pmid 14580962?><pub-id pub-id-type="pmid">14580962</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>NC</given-names></name><name><surname>Addiss</surname><given-names>DG</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>King</surname><given-names>CH</given-names></name><name><surname>Stothard</surname><given-names>JR</given-names></name><name><surname>Evans</surname><given-names>DS</given-names></name><name><surname>Colley</surname><given-names>DG</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Coulibaly</surname><given-names>JT</given-names></name><name><surname>Bustinduy</surname><given-names>AL</given-names></name><etal/></person-group><article-title>A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>2</issue><fpage>e64</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30535-7</pub-id><?supplied-pmid 27914852?><pub-id pub-id-type="pmid">27914852</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustinduy</surname><given-names>AL</given-names></name><name><surname>Friedman</surname><given-names>JF</given-names></name><name><surname>Kjetland</surname><given-names>EF</given-names></name><name><surname>Ezeamama</surname><given-names>AE</given-names></name><name><surname>Kabatereine</surname><given-names>NB</given-names></name><name><surname>Stothard</surname><given-names>JR</given-names></name><name><surname>King</surname><given-names>CH</given-names></name></person-group><article-title>Expanding praziquantel (PZQ) access beyond mass drug administration programs: paving a way forward for a pediatric PZQ formulation for schistosomiasis</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>9</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0004946</pub-id><?supplied-pmid 27658198?><pub-id pub-id-type="pmid">27658198</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olveda</surname><given-names>RM</given-names></name><name><surname>Acosta</surname><given-names>LP</given-names></name><name><surname>Tallo</surname><given-names>V</given-names></name><name><surname>Baltazar</surname><given-names>PI</given-names></name><name><surname>Lesiguez</surname><given-names>JL</given-names></name><name><surname>Estanislao</surname><given-names>GG</given-names></name><name><surname>Ayaso</surname><given-names>EB</given-names></name><name><surname>Monterde</surname><given-names>DB</given-names></name><name><surname>Ida</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><issue>2</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00345-X</pub-id><?supplied-pmid 26511959?><pub-id pub-id-type="pmid">26511959</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Person</surname><given-names>B</given-names></name><name><surname>Ame</surname><given-names>SM</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Muhsin</surname><given-names>J</given-names></name><name><surname>Juma</surname><given-names>S</given-names></name><name><surname>Khamis</surname><given-names>IS</given-names></name><name><surname>Rabone</surname><given-names>M</given-names></name><name><surname>Blair</surname><given-names>L</given-names></name><name><surname>Fenwick</surname><given-names>A</given-names></name><etal/></person-group><article-title>Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey</article-title><source>Parasit Vectors</source><year>2016</year><volume>9</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s13071-015-1244-0</pub-id><?supplied-pmid 26727915?><pub-id pub-id-type="pmid">26727915</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>QB</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>YX</given-names></name><name><surname>Sun</surname><given-names>LP</given-names></name><name><surname>Yang</surname><given-names>GJ</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>LH</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Steinmann</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effectiveness of a comprehensive schistosomiasis japonica control program in Jiangsu province, China, from 2005 to 2008</article-title><source>Acta Trop</source><year>2011</year><volume>120</volume><issue>Suppl 1</issue><fpage>S151</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2010.11.006</pub-id><?supplied-pmid 21147056?><pub-id pub-id-type="pmid">21147056</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergquist</surname><given-names>R</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>McManus</surname><given-names>DP</given-names></name></person-group><article-title>Trick or treat: the role of vaccines in integrated schistosomiasis control</article-title><source>PLoS Negl Trop Dis</source><year>2008</year><volume>2</volume><issue>6</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0000244</pub-id><?supplied-pmid 18575619?><pub-id pub-id-type="pmid">18575619</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebeje</surname><given-names>BM</given-names></name><name><surname>Harvie</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Loukas</surname><given-names>A</given-names></name><name><surname>McManus</surname><given-names>DP</given-names></name></person-group><article-title>Schistosomiasis vaccines: where do we stand?</article-title><source>Parasit Vectors</source><year>2016</year><volume>9</volume><issue>1</issue><fpage>528</fpage><pub-id pub-id-type="doi">10.1186/s13071-016-1799-4</pub-id><?supplied-pmid 27716365?><pub-id pub-id-type="pmid">27716365</pub-id></element-citation></ref></ref-list></back></article>